These findings document the deleterious impact of glucotoxicity on β cell function in patients with T2D and the improvement in β cell function following amelioration of glucotoxicity by the glucosuric effect produced by SGLT2 inhibition. Here, SLC5A2 is linked to type 2 diabetes mellitus.